Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial - Wikidata - wikimedia - TriplyDB

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

http://www.wikidata.org/entity/Q27860949

about

sameAs

Treatment of hepatitis C in children: a systematic review Viral hepatitis and hepatocellular carcinoma A new insight into hepatitis C vaccine development The global spread of hepatitis C virus 1a and 1b: a phylodynamic and phylogeographic analysis PEGylation of Interferon-β-1a Strategies to reduce hepatitis C virus recurrence after liver transplantation New perspectives in occult hepatitis C virus infection Hepatitis C: a review for primary care physicians Pathogenesis of hepatitis C during pregnancy and childhood Nitazoxanide for chronic hepatitis C Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients Interferon for interferon nonresponding and relapsing patients with chronic hepatitis C Nitazoxanide for chronic hepatitis C virus infection Pegylated interferon alpha 2a versus pegylated interferon alpha 2b for chronic hepatitis C Ribavirin plus interferon versus interferon for chronic hepatitis C Pegylated interferon plus ribavirin versus non-pegylated interferon plus ribavirin for chronic hepatitis C Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90 A single-amino-acid mutation in hepatitis C virus NS5A disrupting FKBP8 interaction impairs viral replication Ribavirin enhances interferon signaling via stimulation of mTOR and p53 activities Antiviral therapy of HCV in the cirrhotic and transplant candidate.Identification of hepatoprotective flavonolignans from silymarin Outcomes of treatment for hepatitis C virus infection by primary care providers Vitamin D supplementation improves sustained virologic response in chronic hepatitis C (genotype 1)-naïve patients Hepatitis C virus protease inhibitor-resistance mutations: our experience and review An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases Antiviral drugs for viruses other than human immunodeficiency virus Is pegylated interferon superior to interferon, with ribavarin, in chronic hepatitis C genotypes 2/3?Secondary prevention of recurrence by interferon therapy after ablation therapy for hepatocellular carcinoma in chronic hepatitis C patients Genetic history of hepatitis C virus in East Asia Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys Viral encounters with 2',5'-oligoadenylate synthetase and RNase L during the interferon antiviral response Clinical Profiles of Chronic Hepatitis C in a Major County Medical Center Outpatient Setting in United States.Treatment of acute hepatitis C virus infection with interferon-alpha 2b and ribavirin: case report and review of the literature High versus standard doses interferon-alpha in the treatment of naïve chronic hepatitis C patients in Taiwan: a 10-year cohort study A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease Retreatment of hepatitis C non-responsive to interferon. A placebo controlled randomized trial of ribavirin monotherapy versus combination therapy with Ribavirin and Interferon in 121 patients in the Benelux [ISRCTN53821378]Involvement of PKR and RNase L in translational control and induction of apoptosis after Hepatitis C polyprotein expression from a vaccinia virus recombinant Novel type I interferon IL-28A suppresses hepatitis C viral RNA replication.

P2860

Q21136318-CB670B85-2382-4F03-A2F1-74C601228E68 Q21245597-CB9FF3F9-71FD-44D4-942B-1B8F40A15B0A Q21296858-1D03F410-6147-44D2-B7FC-A024D9FD4D4A Q21563395-B8C6FE7F-120B-4724-8678-F9F9BF0A00A1 Q22241420-B55DF78E-8A07-4C3B-9FEC-C1F8FA59D13C Q22305418-1257DE03-343F-4D7E-BA4F-4E4926010BA5 Q22305491-DB064DD0-7700-4567-9159-16F696109064 Q22306040-6BF5EF3C-AC2A-4B5E-8E18-D06BF2183091 Q22809427-990752D8-D949-4157-A43B-B4D8227ACEA8 Q24197485-FC9C9C78-6470-456C-B997-D9ED062C1825 Q24200189-69597F06-37EE-4207-9956-79FD33AF624E Q24200197-6A236CFD-4EF3-45C0-B715-7A18CE37CEEA Q24200534-FB27ECA9-F5DA-4CD9-9602-8CC1BE117292 Q24201588-A0F87BA4-7B0A-4B6E-A6A4-DB8169DFA68C Q24234215-FC731EB7-8906-42EC-83FC-4DA81E5CDC95 Q24240315-4E80A801-EB6A-4979-A5D7-1B0D00DD4FAF Q24240879-8DD86F79-3E5E-401E-99C4-BA0746F15895 Q24241360-2926DB19-5885-471F-9863-4EAB6A11C7D3 Q24306116-834E2F51-402D-4F70-80F5-A5E55230A3FC Q24307609-4489101B-E527-43C9-A20E-81F74809E412 Q24316273-D9DED4CF-8B61-4E6F-AB96-618D3D69DF73 Q24541565-60991EEF-102D-4766-A61A-8DEF4CD5DD5F Q24600492-9C969C73-138B-4B61-A2D3-5C19310E056C Q24601722-8CBB3210-F4BF-403E-B06D-C6D667C160BC Q24624237-5B06FAF9-28CC-4F38-92CB-59768A2BB714 Q24628717-B3F5BA4D-C82A-4496-9B07-8FA9779DCAE6 Q24632766-20871485-4DA6-4A37-9346-4BBF3E456097 Q24635330-BB1DF944-307A-4472-9B10-69B5240443F8 Q24644729-B91708E7-76F5-47F9-81CF-AA0E3E3038E3 Q24653596-9337C9D8-38ED-4FFD-AB6F-C5B72B2AA3C0 Q24655361-C7896CD2-19A8-411A-87B1-E6BD2085AB4B Q24680380-DF8A8C66-13DD-4CEC-A2FE-A5EED4D42DFE Q24681387-041EA747-3DF6-4CE6-923B-1A3F70993CBC Q24791398-438EC73D-BA86-43D8-9A2B-C5A2BD1E5996 Q24799021-ED80034F-F6D2-4BC2-B52D-BE016AEB4605 Q24799492-2A5BCF20-5DF3-47DA-8A24-9BD3A08BA947 Q24800420-0371B054-E3E8-4D3D-A53D-BEB437C079C1 Q24805127-2EB0FDCA-A674-4737-8754-50FDB750917F Q24814549-721497C7-E921-4832-B5E8-377F03174E85 Q24815995-E8C51B3C-1CF7-4B91-B3C4-9FA2A9A4F58E

P2860

Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial

http://www.wikidata.org/entity/Q27860949

description

2001 nî lūn-bûn

@nan

2001 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@ast

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@en

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@nl

type

label

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@ast

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@en

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@nl

prefLabel

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@ast

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@en

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@nl

P1433

Q27860949-DBAC558A-3C12-447E-8328-2927467931CE

P1476

Q27860949-98252C96-B3B3-4E8E-AAFF-B109EC13EE26

P2093

Q27860949-02E7330A-41E8-44B4-B710-AF87BF0DD6FE

Q27860949-1774E74D-6A4C-403D-9197-DE91DF8A3EFA

Q27860949-3A500FD7-B0D9-4254-B350-107A3FDA056E

Q27860949-3DF67C4E-0B13-4FD4-B45B-72CA67255203

Q27860949-4333255C-6291-4892-B596-55E636A117BE

Q27860949-44247445-C596-4E71-92A7-3F82E0A8D19D

Q27860949-4744CD9C-1B9F-4D91-85BF-7226591AA893

Q27860949-52137E38-24E0-498E-BB7C-086809D7C83C

Q27860949-6DF46528-7FD2-439C-BE99-67A36D5E784F

Q27860949-7A75E4F6-7E81-48C4-8B5E-42702BE5B11F

P304

Q27860949-9F5537DE-14A0-44BA-909D-A4E09EFECDB2

Q27860949-B068059D-D535-4B8A-AAF6-BF7B0907B186

P31

Q27860949-9566087B-F2DC-42DD-892E-34CB97926AA2

P3181

Q27860949-5BBED3F8-8F09-46F6-B978-78D8BA551C2B

P356

Q27860949-1E8ECB91-3B11-4BB3-AB14-F951975D2799

P407

Q27860949-5F463B06-6969-4662-AAC1-0D49E4C1C525

P433

Q27860949-13B3C508-309F-4BFC-837F-684DF886FEBE

P478

Q27860949-6FC0EAA5-353F-4552-BC67-051EF27FFF60

P577

Q27860949-2AB90696-D93E-419E-9B3F-D67C16D12143

Q27860949-50741108-935C-4FD4-A636-ECBBED8CF1BD

P698

Q27860949-73EA63A9-AC2A-41E4-A435-645E7C8BE76F

P921

Q27860949-246dcd9c-4dc0-68e1-0317-46560501af77

Q27860949-36e73f8a-49ac-07bf-2048-0087fe808583

Q27860949-7d2cc885-4b40-996a-9119-552ee43d8d3a

Q27860949-8df57b62-4a55-3e71-415b-25485a02ba64

P3181

P356

S0140-6736(01)06102-5

P1433

P1476

Peginterferon alfa-2b plus rib ...... epatitis C: a randomised trial

@en

P2093

J G McHutchison

http://www.w3.org/2001/XMLSchema#string

J K Albrecht

http://www.w3.org/2001/XMLSchema#string

Janice K Albrecht

http://www.w3.org/2001/XMLSchema#string

John G McHutchison

http://www.w3.org/2001/XMLSchema#string

K Koury

http://www.w3.org/2001/XMLSchema#string

Kenneth Koury

http://www.w3.org/2001/XMLSchema#string

M Ling

http://www.w3.org/2001/XMLSchema#string

M P Manns

http://www.w3.org/2001/XMLSchema#string

M Shiffman

http://www.w3.org/2001/XMLSchema#string

Mei-Hsiu Ling

http://www.w3.org/2001/XMLSchema#string

P304

958-65

http://www.w3.org/2001/XMLSchema#string

958-965

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

408785

http://www.w3.org/2001/XMLSchema#string

P356

10.1016/S0140-6736(01)06102-5

http://www.w3.org/2001/XMLSchema#string

P407

P433

9286

http://www.w3.org/2001/XMLSchema#string

P478

358

http://www.w3.org/2001/XMLSchema#string

P577

2001-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

2001-09-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

11583749

http://www.w3.org/2001/XMLSchema#string

P921

Peginterferon alfa-2a